Article: O.3 Comparison of 2 nonmyeloablative regimens for allogeneic HCT: a phase II randomized study from the HCT committee of the BHS

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma